Pharmacyclics – Leader in Targeted Hematology Oncology
Pharmacyclics LLC
Pharmacyclics LLC is an American biopharmaceutical company founded in 1991 in Sunnyvale, California, by scientists Jonathan Sessler and Richard Miller. AbbVie acquired it in 2015 for about 21 billion dollars, and Pharmacyclics has operated as an AbbVie subsidiary since then.
The company focuses on haematologic cancers. Its main product is Imbruvica (ibrutinib), the first-in-class inhibitor of Bruton's tyrosine kinase (BTK). Pharmacyclics acquired the molecule in 2006, together with several other drug candidates, from Celera Genomics.
In December 2011 Pharmacyclics signed an agreement with Janssen (part of Johnson & Johnson) to jointly develop and commercialise ibrutinib: both companies sell it in the US, and Janssen sells it in the rest of the world. Imbruvica received its first FDA approval on 13 November 2013, for previously treated mantle cell lymphoma. Its indications later expanded to chronic lymphocytic leukaemia, Waldenström's macroglobulinaemia and chronic graft-versus-host disease.
Unifarm carries Pharmacyclics' Imbruvica 140 (ibrutinib).